

April 28, 2023

OTC Markets Group Inc.
Attention: Issuer Services
304 Hudson Street, Second Floor
New York, NY 10013111 Broadway
Suite 807
New York, NY 10006T – (212) 417-8160
F – (212) 417-8161

www.lucbro.com**Re: Attorney Letter with Respect to Adequate Current Information of Curative
Biotechnology, Inc. (the “Issuer”)**

We have been asked to provide you with a letter with respect to (1) the Issuer’s 2022 Annual Report and Financial Statements for the period ending December 31, 2022, published on the OTC Disclosure and News Service on April 7, 2023 (the “Company Material”). In connection with this letter, we have reviewed the Company Material and based our opinion on such information. This letter is solely for the information of OTC Markets Group, Inc. which is entitled to rely on this letter in determining if the Issuer has provided adequate public disclosure of information within the meaning of Rule 144(c)(2) promulgated under the Securities Act of 1933, as amended (the “Securities Act”).

The undersigned is a resident of the United States and has been retained by the Issuer for the purposes of rendering this letter and related matters. We have been retained as special counsel to review this disclosure for the Issuer. This letter is based upon our knowledge of the law and the facts of the date hereof.

In connection with the rendering of this opinion, we have examined such corporate records and other documents and such questions of law as counsel considered necessary or appropriate for purposes of rendering this letter. Lucosky Brookman LLP is a New Jersey Limited Liability Partnership. We are authorized to practice law in the State of New York and the State of New Jersey. Our law firm is permitted to practice before the Securities and Exchange Commission and has not been prohibited from practice thereunder. Our law firm has never been barred from practice in any of the foregoing jurisdictions. In the past five years, our law firm has not been and is not the subject of an investigation, hearing or proceeding by the SEC, the US Commodity Futures Commission (CFTC), the Financial Industry Regulatory Authority (FINRA) or any other federal, state or foreign regulatory agency.

In our capacity as counsel, we have examined originals or copies, certified or otherwise, identified to our satisfaction as being true copies, of the Articles of Incorporation, as amended, of the Issuer, and such corporate records of the Issuer, certificates of public officials and of officers and directors of the Issuer and others (all of whom were believed to be reliable), and other documents as we have deemed necessary for the purposes of this letter. For the purpose of this letter, we have assumed (1) the genuineness of all signatures and the authenticity and completeness of all corporate records,

certificates of officers, certificates of public officials, and other documents and instruments submitted to us as originals; (2) the conformity of authentic originals of all corporate records, certificates of officers, certificates of public officials, and other documents and instruments submitted to us as certified, conformed, photo static or facsimile copies thereof; and (3) the accuracy and adequacy of disclosures made to me by the Issuer's management including, without limitation, the financial information contained in the Information. We have no reason to believe that such records, certificates and other documents are not accurate, authentic or reliable and we make no assurances as to the accuracy and adequacy of such documents.

In connection with this letter, we have reviewed the following Issuer's filings (the "Information") posted on the OTC Disclosure and News Service:

The above-referenced reports have accompanying notes which are integral to such statements and are to be considered by any interested parties. In issuing this letter, we represent as follows:

1. The foregoing and any following additional information (i) constitutes "adequate current public information" concerning the Issuer and is "available" within my understanding of the meaning of Rule 144(c)(2) under the Securities Act; (ii) includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Securities under Rule 15c2-11 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"); (iii) complies as to form with the OTC Markets Group's OTC Pink Disclosure Guidelines, which are located on the Internet at www.otcm Markets.com; and (iv) has been posted through the OTC Disclosure and News Service.
2. The financial statements of the issuer contained in the Information were not audited and were prepared by Michael K. Fish, CPA, director of the Issuer, or under his direction. Mr. Fish has over five years of business experience in the financial sector and had provided accounting and financial consulting services to private companies.
3. The Issuer's transfer agent (the "Transfer Agent") is Issuer Direct Corporation, One Glenwood Avenue, Suite 1001, Raleigh, NC 27603, (919) 481-4000. The Transfer Agent is registered with the Securities and Exchange Commission. The method used by counsel to confirm the number of outstanding shares was review of the shareholders' list generated by the Transfer Agent.
4. That we have (i) met with the management of the Issuer and with Michael K. Fish, through video conference call, (ii) reviewed the Information, as amended, published by the Issuer through the OTC Disclosure and News Service and (iii) discussed the information with management and its director.
5. To the best of our knowledge, and after reasonable inquiry of the Issuer's management and directors, there is no officer, director, 5% holder or counsel currently under investigation by any federal or state regulatory agency for any violation of federal or state securities laws.
6. The undersigned does not own, beneficially or otherwise, any shares of the Issuer's securities and has not agreed to accept any securities from the Issuer for her services in the future.

7. Counsel is not currently, or in the past five years, suspended or barred from practicing in any state or jurisdiction, and whether counsel has been charged in a civil or criminal case.
8. Based on its Annual Report for the year ended December 31, 2022, the Issuer indicates it is currently not a “shell company” as defined in Rule 405 of the Securities Act and 12b2 of the Exchange Act. As of December 31, 2022, the Issuer’s financial statements indicated that it had total assets of \$2,089,191 and total current liabilities of \$4,487,103. The Issuer reported net losses of \$5,604,893 for the year ended December 31, 2022.

Based solely on the representations of the Company, its management and board of directors, the Company is not and has never been a “shell company” as defined in Rules 405 of the Securities Act of 1933 and 12b-2 of the Exchange Act. This letter is limited to the date hereof and we do not in any event undertake to advise you of any facts or circumstances occurring or coming to our attention subsequent to the date hereof.

This letter may be relied upon only by OTC Markets Group, Inc. and may not be relied upon by any other person or entity without my prior written consent; however, we hereby grant OTC Markets Group, Inc. full and complete permission and rights to publish the letter through the OTC Disclosure and News Service for viewing by the public and regulators.

This opinion is solely for the information of the addressee hereof and the other parties specifically identified in the first paragraph hereof and is not to be quoted in whole or in part or otherwise referred to, nor is it to be filed with any governmental agency or other person without our prior written consent. Other than the addressee hereof and such other parties, no one is entitled to rely upon this letter.

Very Truly Yours,

Lucosky Brookman LLP

/s/ Amit Hazan

Amit Hazan, Esq.